Enabling innovation for under-researched infectious diseases

Governing Board Evaluation Dates

  • Governing Board Evaluation Dates

    The Governing Board members will meet three times during 2020 to review new proposals. Proposals need to be submitted 6 weeks prior to the GB evaluation date.

    • 18th March 2021
    • 23rd June 2021
    • 18th Nov 2021

    Call open all year.

    Please visit "Submit project Proposal”, where you will find the documents we are asking you to complete to apply for a TCOLF grant.


    IN ADDITION TO TUBERCULOSIS, MALARIA, KINETOPLASTIDS AND ENTERIC INFECTIONS, The Tres Cantos Open Lab Foundation invites applications for projects with a focus on prevention and/or treatment of EED

    BACKGROUND: EDD, an incompletely defined subclinical in-flammatory disorder of the small intestine, is emerging as the underlying cause of stunting and may explain at least 40% of all cases of stunting even after controlling for diarrhoea and re-duced efficacy of enteric vaccines in development countries. The condition, is thought to be a result of living in unsanitary conditions, under-nutrition and ingestion of faecal bacteria, and is characterized by the flattening of villi, increase in crypt depth, reduction of absorptive capacity and reduced barrier function resulting in bidirectional leakage of fluid, bacteria and toxins across the gut wall.


    SCIENTIFIC OPPORTUNITY: Current health and nutrition programmes are having a limited impact to mitigate EED effects. TCOLF is looking for innovative opportunities to complement these strat-egies. These opportunities include but are not limited to -biotics, hits/leads and drug assets (marketed or in develop-ment) that exploit the pathophysiology of EED.

    About this call—Key areas of interest:

    • Exploitation of new targets towards EED treatment
    • Phenotypic in vitro assays that allow identification of hits (single cell, co-culture, organoids, etc)
    • Medicinal chemistry optimisation of hits/leads
    • Animal models that allow evaluation and establishment of PK/PD relationships
    • Biopharmaceutical/microbiome-based approaches

    More information about TCOLF
    Ballell, L. et al. Nat Rev Drug Discov, 15, 292 (2016)


    The Tres Cantos Open Lab Foundation invites applications for projects with a focus on treatment for tuberculosis. The foundation will continue fund-ing drug discovery projects in MALARIA, KINETOPLASTIDS AND ENTERIC INFECTIONS

    BACKGROUND: According to the 2018 Global Tuberculosis (TB) report published by the WHO,1 10m people developed TB disease yielding to an estimated 1.3m deaths, during 2017. In addition, it estimated that 23% of the world’s population (1.7bn people), are at risk of developing the disease during their life-time as they have a latent TB infection. In an unprecedent step forward to tackle the epidemic, on the 26th September 2018 at the UN headquarters in New York, the first-ever high-level meeting on TB took place. The theme of the meeting was “United to end TB: an urgent global response to a global epidemic”. The final resolution of the meeting highlights the need investment in research as a critical factor to achieve the objectives.


    Left /right picture: 3D reconstruction of a thorax and lungs Computed Tomo-graphy of a Mtb infected mouse showing a cavity / Histopathology of lungs from an Mtb infected mouse showing necrotic granulomas.2

    ABOUT THIS CALL: TCOLF is looking for innovative science-led opportunities to collaborate in the discovery of new drugs to treat the disease. Key areas of interest include:

    • The development of new platforms/tools to support non-conventional antitubercular drug discovery programs fo-cused on Host Pathogen Interactions.
    • Development of tools to unveil the mode of action of host/virulence directed therapies.
    • Research on regimen drug selection and strategies for treatment shortening.
    • New chemical diversity (screening and hit/lead optimizati-on) including Target-based programs with a strong rational design component.

    More information about TCOLF
    Ballell, L. et al. Nat Rev Drug Discov, 15, 292 (2016)